𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Initial pharmacokinetic studies on the potent HIV-1 and HIV-2 inhibitors PVAS and PAVAS : M. Witvrouw1, D. Schols1, R. Pauwels1, S. Görög2 and E. De Clercq2 Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium1 and Chemical Works of Gedeon Richter Ltd., Budapst, Hungary2

Book ID
118392370
Publisher
Elsevier Science
Year
1990
Tongue
English
Weight
67 KB
Volume
13
Category
Article
ISSN
0166-3542

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HIV-1 specific phenylacetamide derivativ
HIV-1 specific phenylacetamide derivatives: A novel class of reverse transcriptase inhibitors with potent and selective antiviral activity in vitro : R. Pauwels1, K. Andries2, Z. Debyser1, P. Van Daele2, D. Schols1, M.A.C. Janssen2, J. Desmyter1, E. De Clercq1 and P.A.J. Janssen2 1Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium and 2Janssen Research Foundation, B-2340 Beerse, Belgium
📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 72 KB
140 Effects of combinations of HIV-1 spe
140 Effects of combinations of HIV-1 specific RT inhibitors with complementary resistance profiles on the time and type of drug-resistant HIV-1 development: R. Pauwels1, M.P. de Béthune1, K. Andries2, P. Stoffels2, J. Desmyter1, P.A.J. Janssen2 and E. De Clercq1 1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium and 2Janssen Research Foundation, Beerse, Belgium
📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 81 KB
The thiocarboxanilides UC-781 and UC-82
The thiocarboxanilides UC-781 and UC-82 are potent HIV-1-specific reverse transcriptase inhibitors that inhibit a broad spectrum of drug-resistant HIV-1 strains: J. Balzarini1, C.-F. Perno2, D. Schols1, M. Witvrouw1, E. De Clercq1 and A. Karlsson3 1Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium; 2University of Rome “Tor Vergata”, Rome, Italy; 3Karolinska Institute, Stockholm, Sweden
📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 111 KB
3 Highly selective and potent inhibition
3 Highly selective and potent inhibition of human immunodeficiency virus (HIV) by the novel bicyclam derivative JM31000: E. De Clercq1, N. Yamamoto1, R. Pauwels1, M. Witvrouw1, K. De Vreese1, Z. Debyser1, R. Skerlj3, D. Thornton2, G. Bridger3, G. Henson3 and M. Abrams3 1Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; 2Johnson Matthey Technology Centre, Sonning Common, Reading RG4 9NH, United Kingdom; and 3Johnson Matthey Pharmaceutical Research, West Chester, Pennsylvania 19380, USA
📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 71 KB
TIBO derivatives represent a new lead of
TIBO derivatives represent a new lead of potent and selective HIV-1 inhibitors that interact with a reverse transcriptase-associated process : R. Pauwels1, K. Andries2, D. Schols1, Z. Debyser1, H. Nakashima, M. Kukla3, J. Desmyter1, E. De Clercq1 and P.A.J. Janssen2 Rega Institute for Medical Research, Katholieke Universiteir Leuven, B-3000 Leuven, Belgium1, Janssen Research Foundation, B-2340 Beerse, Belgium2 and Janssen Research Foundation, Spring House, Pennsylvania 19477, USA3
📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 52 KB